Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to $498.4 million.

  • Immunocore Holdings' Cash & Equivalents fell 731.8% to $498.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $498.4 million, marking a year-over-year decrease of 731.8%. This contributed to the annual value of $455.7 million for FY2024, which is 296.07% up from last year.
  • Per Immunocore Holdings' latest filing, its Cash & Equivalents stood at $498.4 million for Q3 2025, which was down 731.8% from $487.9 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Cash & Equivalents peaked at $832.8 million during Q1 2024, and registered a low of $321.1 million during Q4 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $444.5 million (2023), whereas its average is $468.2 million.
  • In the last 5 years, Immunocore Holdings' Cash & Equivalents surged by 9952.35% in 2024 and then crashed by 4274.34% in 2025.
  • Over the past 5 years, Immunocore Holdings' Cash & Equivalents (Quarter) stood at $321.1 million in 2021, then increased by 25.32% to $402.5 million in 2022, then rose by 9.98% to $442.6 million in 2023, then increased by 2.96% to $455.7 million in 2024, then increased by 9.37% to $498.4 million in 2025.
  • Its Cash & Equivalents stands at $498.4 million for Q3 2025, versus $487.9 million for Q2 2025 and $476.8 million for Q1 2025.